Health Professional Radio - Podcast

Dr. Tere Linzey, a Licensed Educational Psychologist and founder of BrainMatterZ discusses Brain Optimization and cognitive training that can greatly improve a child's scholastic performance.

J.G. Jones, a comic book artist, discusses his journey living with a myeloproliferative neoplasm, a type of rare blood cancer, that was diagnosed 10 years ago, and his participation in "Rare Reflections: MPNs Unmasked", a new campaign sponsored by Incyte which will feature a series of portraits by J.G. of real MPN patients and caregivers.

Research scientist at Kaiser Permanente Division of Research, Dr. Candyce Kroenke, MPH, ScD, discusses recent research that indicated post-menopausal women with colorectal cancer would die sooner from their disease if they had a lack of support from their families, friends and social networks when they were diagnosed than those who had high levels of support. This research underscores the importance of identifying patients at risk of low social support and providing them with additional resources, including emotional support and logistical help.

Dr. Paul Martinez, a Critical Care Medicine physician at Nicklaus Children’s Hospital in Miami, FL discusses the clinical perspective on teen vaping.

G.T. LaBorde, CEO of IllumiCare discusses recent data that reveals that for each additional specialist seen, patients will stay about one extra day in the hospital. With the national average for a hospital stay at 4.5 days, according to the Agency for Healthcare Research and Quality, fragmentation of specialties in the inpatient setting may be fostering inefficiencies.

Judy Gaman, an award-winning author, public speaker, and CEO of Executive Medicine of Texas, talks about her upcoming book "Love, Life, & Lucille: Lessons from a Centenarian" (April 2020).

Jude Bond, CEO of Cannaphyll™ Hemp-Infused Topicals, discusses Cannaphyll's patent-pending blend of organic phylloceuticals that improves endocannabinoid uptake and delivery. Targeted to active-lifestyle boomers, fitness-enthusiast Gen-Xers, mobility-challenged seniors, high-performance athletes, and chronic pain sufferers, Cannaphyll™ provides more than 1,000mg premium Hemp Extract per 1 ounce, making it more potent than virtually all other OTC hemp-infused topical creams.

Dr. Joe Powers, Chief Strategy Officer at AppliedVR, discusses the collaboration between AppliedVR and the National Cancer Institute, part of the National Institute of Health, to evaluate virtual reality (VR) therapeutics as a solution to help cancer patients suffering from stress and anxiety.

Ariel talks about her journey of finally receiving a diagnosis of acute hepatic porphyria (AHP), a rare disease characterized by potentially life-threatening pain attacks. She is now able to manage her disease. She also discusses her experience being treated with Alnylam Pharmaceutical's GIVLAARI™ (givosiran) a drug approved by the FDA in November 2019 for the treatment of AHP.

John Temperato, CEO of RDD Pharma and what will be 9 Meters Biotechnology, discusses GI diseases, current treatments, why there are still unmet needs for diseases like celiac and others, and what's on the horizon. Through the RDD/Innovate merger, 9 Meters will have larazotide, the first-ever drug candidate to enter Phase 3 registration trials for celiac disease.

Dr. Andrew Pecora, CEO of Outcomes Matter Innovations (OMI), a company looking to improve patient results by increasing the value of each doctor’s visit, discusses the problems and offers solutions, such as changing the payment model and taking administrative work off physicians.

Dr. Russell Basser, MD, Chief Scientist and Senior VP of Research and Development at Seqirus, discusses the FDA approval of Seqirus's AUDENZ™ (Influenza A (H5N1) Monovalent Vaccine, Adjuvanted). This is the first-ever adjuvanted, cell-based pandemic influenza vaccine to protect against influenza A (H5N1) – a subtype of influenza that the U.S. Centers for Disease Control and Prevention says has strong pandemic potential.

Dr. Janet Kennedy, a clinical psychologist, sleep specialist and author of "The Good Sleeper " and Mary van Praag, President of the Intimates Group of Chico’s FAS, discuss tips for establishing a nighttime routine and share insights on rest from Soma’s national sleep study.

Dr. Neil Hayward, co-founder, President, and CEO at eXIthera Pharmaceuticals, Inc., discusses the need for a new anti-thrombotic drug and how eXIthera is addressing that need with their lead product candidate EP-7041. The next step for EP-7041 is Phase 2 clinical trials on cardiac surgery patients.

Martin Burns, CEO of BBI (Bruin Biometrics), discusses preventing pressure injuries, the recently updated guidelines by the National Pressure Injury (formerly Ulcer) Advisory Panel, and the financial impact of pressure injuries and how the system can incorporate major change. After crunching the numbers, analyzing the data and developing technology to create a solution, he believes that true prevention of pressure injuries can finally be made real.

Dr. William Chey, MD, a Professor of Gastroenterology & Nutrition Sciences, and Director of the GI Nutrition and Behavioral Wellness Program, University of Michigan Health System, discusses the findings from a survey called "Current Insights About Constipation" that was conducted by The Harris Poll on behalf of Shire (now Takeda) that shows the extent Chronic Idiopathic Constipation (CIC) has on daily life though few people talk about it. This year's sub-analysis of the survey was done looking specifically at how women are impacted by CIC.

Dr. Jeff Sharman of Willamette Valley Cancer Institute and Research Center and Nichole Fisher, RN, BSN, discuss recent research presented at the 2019 American Society of Hematology (ASH) Annual Meeting, the current treatment landscape for CLL, and the impact a diagnosis can have on a patient and their loved ones.

Morris Miller, CEO of Xenex Disinfection Services talks about hospital-acquired infections (HAIs) and the Xenex® LightStrike™ Germ-Zapping™ Robot that is proven to kill superbugs like MRSA and C. diff on high touch surfaces.

Returning guest Dr. Scot Ebbinghaus discusses the recent (Jan 2020) FDA approval of Merck's KEYTRUDA® (pembrolizumab) for patients with BCG-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma In situ with or without papillary tumors who are Ineligible for or have elected not to undergo cystectomy.

Edouard Saget, Co-Founder, Board Member, and Co-CEO of OrthoGrid Systems, a Salt Lake City-based global medtech leader offering intraoperative alignment technologies that work across all orthopedic implants, discusses the partnership with the University of Utah Hospital. This partnership provides orthopedic surgeons with the latest technology in surgical precision, reducing hospital readmissions and improving patient outcomes for a variety of procedures, including total hip replacement, knee replacement or reconstruction, and total joint arthroplasty. OrthoGrid's software technology is used directly in the OR via surgeons' existing imaging tools, providing accuracy in a field where it's extremely important and could impact leg length discrepancies, alignment, and overall mobility.